Pfizer names Cecile Guegan permanent CFO, effective November 1

Pfizer Inc. announced on November 3, 2026 that its Board of Directors had unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026.¹ Guegan had served as interim Chief Financial Officer since August 16, 2026, steering the company's financial operations, execution and strategic planning.¹

The accompanying Form 8-K states that Guegan, 55, was previously appointed as the company's Interim Chief Financial Officer effective August 16, 2026, as reported in a Form 8-K filed June 18, 2026.¹

In the new role, Guegan will oversee every aspect of the company's financial management, including audit, treasury, investor relations, tax, insurance, operations planning and analysis, corporate controllership, and business finance and analytics.¹

On her background, the filing notes she has more than 25 years of global finance leadership in the pharmaceutical industry.¹ She joined Pfizer in connection with its 2009 acquisition of Wyeth, where she had served as chief financial officer supporting the Asia Pacific and EMEA/Canada businesses.¹ At Pfizer, she has held successive finance leadership roles across Oncology, Research and Development, and the Global Biopharmaceuticals Group.¹ Immediately before her appointment as Interim Chief Financial Officer, she served as Senior Vice President of Finance for Pfizer's Global Biopharmaceuticals business since 2022 and Vice President, Finance, Research & Development and Business Office from 2020 to 2022.¹

Pfizer also disclosed compensation terms: the Compensation Committee approved an annual base salary of $1,300,000 and an annual target cash incentive opportunity of $1,300,000, representing 100% of her base salary, based on salary paid during the year.¹

Guegan holds a master's degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting (French DECF).¹